Phase I study of multiple dose intramuscularly administered recombinant gamma interferon

R. Kurzrock, J. R. Quesada, M. Talpaz, E. M. Hersh, J. M. Reuben, S. A. Sherwin, J. U. Gutterman

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-γ). Forty-four patients with metastatic cancer were given rIFN-γ at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-γ resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for antiinterferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regressison consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-γ are indicated.

Original languageEnglish (US)
Pages (from-to)1101-1109
Number of pages9
JournalJournal of Clinical Oncology
Issue number7
StatePublished - 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase I study of multiple dose intramuscularly administered recombinant gamma interferon'. Together they form a unique fingerprint.

Cite this